Real-World Efficacy Outcomes of FLT3-ITD Acute Myeloid Leukemia Patients Treated with Midostaurin in Combination with Intensive Induction

Acute myeloid leukemia (AML) patients harboring FLT3-ITD mutations are a high-risk patient subset owing to the increased risk of relapse and inferior overall survival (OS) associated with FLT3-ITD.1 While FLT3-ITDmut patients, following receipt of induction, attain comparable remission rates to patients without FLT3-ITD, these patients, especially those with higher allelic ratios are more likely to experience relapse, even after being referred to allogeneic transplantation.2,3 This has led the field to focus on the development of specific inhibitors to FLT3 with the anticipation that these agents would improve outcomes for FLT3-ITDmut patients.